NYSE:ELANPharmaceuticals
A Look At Elanco Animal Health (ELAN) Valuation As Befrena Launch Expands Pet Dermatology Portfolio
Elanco Animal Health (ELAN) has kicked off a phased launch of Befrena, an anti IL 31 monoclonal antibody injection for canine allergic and atopic dermatitis, giving investors fresh information on its pet dermatology portfolio.
See our latest analysis for Elanco Animal Health.
Elanco's recent Befrena launch comes as momentum in the stock has picked up in the short term, with a 7 day share price return of 12.48% and a 1 month share price return of 8.26%, even though the 3 month share price...
